[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

IT1261787B - Metodologia per la selezione di superagonisti, antagonisti e super- antagonisti di ormoni del cui complesso recettoriale fa parte gp 130. - Google Patents

Metodologia per la selezione di superagonisti, antagonisti e super- antagonisti di ormoni del cui complesso recettoriale fa parte gp 130.

Info

Publication number
IT1261787B
IT1261787B ITRM930409A ITRM930409A IT1261787B IT 1261787 B IT1261787 B IT 1261787B IT RM930409 A ITRM930409 A IT RM930409A IT RM930409 A ITRM930409 A IT RM930409A IT 1261787 B IT1261787 B IT 1261787B
Authority
IT
Italy
Prior art keywords
antagonists
site
interleukin
superagonists
hormones
Prior art date
Application number
ITRM930409A
Other languages
English (en)
Inventor
Rocco Savino
Armin Lahm
Gennaro Ciliberto
Original Assignee
Angeletti P Ist Richerche Bio
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Angeletti P Ist Richerche Bio filed Critical Angeletti P Ist Richerche Bio
Publication of ITRM930409A0 publication Critical patent/ITRM930409A0/it
Priority to ITRM930409A priority Critical patent/IT1261787B/it
Priority to ES94920582T priority patent/ES2144524T3/es
Priority to PCT/IT1994/000095 priority patent/WO1995000852A2/en
Priority to HK98111980.2A priority patent/HK1011081B/en
Priority to CN02107480.1A priority patent/CN1249439C/zh
Priority to CN94190533.0A priority patent/CN1101937C/zh
Priority to AT94920582T priority patent/ATE189528T1/de
Priority to DK94920582T priority patent/DK0656117T3/da
Priority to JP7502633A priority patent/JP2643604B2/ja
Priority to PT94920582T priority patent/PT656117E/pt
Priority to AU71324/94A priority patent/AU687416B2/en
Priority to DE69422893T priority patent/DE69422893T2/de
Priority to CA002142973A priority patent/CA2142973C/en
Priority to EP94920582A priority patent/EP0656117B1/en
Publication of ITRM930409A1 publication Critical patent/ITRM930409A1/it
Priority to US08/567,047 priority patent/US5789552A/en
Priority to US08/567,048 priority patent/US5891998A/en
Application granted granted Critical
Publication of IT1261787B publication Critical patent/IT1261787B/it
Priority to GR20000400800T priority patent/GR3033111T3/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Si è trovato che i ligandi del gruppo delle citochine simili alla interleuchina 6 (IL-6), vale a dire Oncostatina M (OSM), Leukemia Inhibitory Factor (LIF), Ciliary Neurotrophic Factor (CNTF) e interleuchina 11 (IL-11), inducono la formazione di un complesso recettoriale di cui fa parte la molecola di membrana gp 130. Si può pertanto ipotizzare che due diverse superfici della proteina (in questa classe di ormoni), definite come sito 1 e sito 2, si legano a due diverse molecole: il sito 1 con il recettore specifico e il sito 2 con gp 130. L'invenzione permette l'identificazione di questi siti e l'isolamento di varianti che hanno, rispetto all'ormone selvatico, una maggiore affinità per il recettore specifico (superagonisti e superantagonisti) oppure una affinità ridotta o nulla per gp 130 (antagonisti e superantagonisti). La figura mostra il costrutto pHen?hIL-6 e la produzione di particelle fasmidiche che sono utilizzabili per la selezione di agonisti dell'interleuchina 6.
ITRM930409A 1993-06-23 1993-06-23 Metodologia per la selezione di superagonisti, antagonisti e super- antagonisti di ormoni del cui complesso recettoriale fa parte gp 130. IT1261787B (it)

Priority Applications (17)

Application Number Priority Date Filing Date Title
ITRM930409A IT1261787B (it) 1993-06-23 1993-06-23 Metodologia per la selezione di superagonisti, antagonisti e super- antagonisti di ormoni del cui complesso recettoriale fa parte gp 130.
JP7502633A JP2643604B2 (ja) 1993-06-23 1994-06-23 受容体複合体がｇｐ１３０を含むホルモンのスーパーアゴニスト，アンタゴニスト，及びスーパーアンタゴニストを選択するための方法
AU71324/94A AU687416B2 (en) 1993-06-23 1994-06-23 A methodology for selecting superagonists, antagonists and superantagonists of hormones whose receptor complex includes GP 130
HK98111980.2A HK1011081B (en) 1993-06-23 1994-06-23 A methodology for selecting superagonists, antagonists and superantagonists of hormones whose receptor complex includes gp 130
CN02107480.1A CN1249439C (zh) 1993-06-23 1994-06-23 一种白细胞介素6受体拮抗剂
CN94190533.0A CN1101937C (zh) 1993-06-23 1994-06-23 一种筛选利用膜分子gp130激活细胞生理调节机制的激素的拮抗剂和超拮抗剂的方法
AT94920582T ATE189528T1 (de) 1993-06-23 1994-06-23 Methode zur auswahl von superagonisten, antagonisten und superantagonisten von interleukin 6
DK94920582T DK0656117T3 (da) 1993-06-23 1994-06-23 Fremgangsmåde til udvælgelse af superagonister, antagonister og superantagonister for interleukin 6
ES94920582T ES2144524T3 (es) 1993-06-23 1994-06-23 Metodologia para seleccionar superagonistas, antagonistas y superantagonistas de la interleuquina 6.
PT94920582T PT656117E (pt) 1993-06-23 1994-06-23 Metodo de seleccao de superagonistas de antagonistas e de superantagonistas da interleucina 6
PCT/IT1994/000095 WO1995000852A2 (en) 1993-06-23 1994-06-23 A methodology for selecting superagonists, antagonists and superantagonists of hormones whose receptor complex includes gp 130
DE69422893T DE69422893T2 (de) 1993-06-23 1994-06-23 Methode zur auswahl von superagonisten, antagonisten und superantagonisten von interleukin 6
CA002142973A CA2142973C (en) 1993-06-23 1994-06-23 A methodology for selecting superagonists, antagonists and superantagonists of hormones whose receptor complex includes gp 130
EP94920582A EP0656117B1 (en) 1993-06-23 1994-06-23 A methodology for selecting superagonists, antagonists and superantagonists of interleukin 6
US08/567,047 US5789552A (en) 1993-06-23 1995-12-04 Interleukin-6 receptor antagonists
US08/567,048 US5891998A (en) 1993-06-23 1995-12-04 Interleukin-6 receptor agonists
GR20000400800T GR3033111T3 (en) 1993-06-23 2000-03-29 A methodology for selecting superagonists, antagonists and superantagonists of hormones whose receptor complex includes gp 130.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ITRM930409A IT1261787B (it) 1993-06-23 1993-06-23 Metodologia per la selezione di superagonisti, antagonisti e super- antagonisti di ormoni del cui complesso recettoriale fa parte gp 130.

Publications (3)

Publication Number Publication Date
ITRM930409A0 ITRM930409A0 (it) 1993-06-23
ITRM930409A1 ITRM930409A1 (it) 1994-12-23
IT1261787B true IT1261787B (it) 1996-06-03

Family

ID=11401818

Family Applications (1)

Application Number Title Priority Date Filing Date
ITRM930409A IT1261787B (it) 1993-06-23 1993-06-23 Metodologia per la selezione di superagonisti, antagonisti e super- antagonisti di ormoni del cui complesso recettoriale fa parte gp 130.

Country Status (13)

Country Link
EP (1) EP0656117B1 (it)
JP (1) JP2643604B2 (it)
CN (2) CN1101937C (it)
AT (1) ATE189528T1 (it)
AU (1) AU687416B2 (it)
CA (1) CA2142973C (it)
DE (1) DE69422893T2 (it)
DK (1) DK0656117T3 (it)
ES (1) ES2144524T3 (it)
GR (1) GR3033111T3 (it)
IT (1) IT1261787B (it)
PT (1) PT656117E (it)
WO (1) WO1995000852A2 (it)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1276555B1 (it) * 1995-04-28 1997-11-03 Angeletti P Ist Richerche Bio Antagonisti di interluchina-6 umana del tutto incapaci di formare un legame con gp 130, e loro uso per la preparazione di composizioni
IT1277926B1 (it) * 1995-09-01 1997-11-12 Angeletti P Ist Richerche Bio Uso di muteine di citochine naturali come immunogeni per la preparazione di composizioni farmaceutiche per curare o prevenire
US5849293A (en) * 1996-01-11 1998-12-15 Cornell Research Foundation, Inc. Use of human transferrin in controlling insulin levels
IT1285790B1 (it) * 1996-09-24 1998-06-24 Angeletti P Ist Richerche Bio Adenovirus difettivi ricombinanti che codificano per mutanti di interleuchina 6 umana (hil-6) con attivita' antagonista o
EP0983767B1 (en) 1997-03-21 2008-09-10 Chugai Seiyaku Kabushiki Kaisha Preventives or remedies for the treatment of multiple sclerosis containing antagonist anti-IL-6-receptor antibodies
GB9806530D0 (en) 1998-03-26 1998-05-27 Glaxo Group Ltd Inflammatory mediator
EA006881B1 (ru) 2001-10-11 2006-04-28 Апплайд Резеч Системз Арс Холдинг Н.В. ПРИМЕНЕНИЕ АКТИВАТОРОВ gp130 ПРИ ДИАБЕТИЧЕСКОЙ НЕВРОПАТИИ
FR2833011B1 (fr) * 2001-12-04 2004-10-29 Univ Claude Bernard Lyon Nouvelle proteine a activite inhibitrice de l'il-6
IL161673A0 (en) 2004-04-29 2004-09-27 Applied Research Systems Compositions and methods for therapy of chemotherapy-induced neuropathy
CN101246160B (zh) * 2007-09-06 2012-11-21 三峡大学 在体外用ELISA方法建立的IL-6/sIL-6R结合的分子模型
DE102011104822A1 (de) 2011-06-18 2012-12-20 Christian-Albrechts-Universität Zu Kiel Ciliary-Neutrophic-Factor-Varianten
WO2013147153A1 (ja) 2012-03-29 2013-10-03 株式会社未来創薬研究所 抗ｌａｍｐ５抗体およびその利用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2345497A1 (en) * 1988-10-28 1990-04-28 Genentech, Inc. Growth hormone variants and method for forming growth hormone variants
JP2898064B2 (ja) * 1989-08-03 1999-05-31 忠三 岸本 ヒトｇｐ１３０蛋白質
JP2898040B2 (ja) * 1990-01-26 1999-05-31 忠三 岸本 ｇｐ１３０蛋白質に対する抗体
US5210075A (en) * 1990-02-16 1993-05-11 Tanabe Seiyaku Co., Ltd. Interleukin 6 antagonist peptides
ATE196548T1 (de) * 1991-05-10 2000-10-15 Genentech Inc Auswählen von agonisten und antagonisten von liganden
CA2147466A1 (en) * 1992-10-20 1994-04-28 Just P. J. Brakenhoff Interleukin-6 receptor antagonists
US5470952A (en) * 1993-10-20 1995-11-28 Regeneron Pharmaceuticals, Inc. CNTF and IL-6 antagonists
US5939534A (en) * 1993-12-29 1999-08-17 Sumitomo Pharmaceuticals Company, Limited Factors mutated in the D1 cap region

Also Published As

Publication number Publication date
ITRM930409A0 (it) 1993-06-23
EP0656117A1 (en) 1995-06-07
CA2142973C (en) 2004-10-26
PT656117E (pt) 2000-07-31
DE69422893D1 (de) 2000-03-09
CA2142973A1 (en) 1995-01-05
AU7132494A (en) 1995-01-17
ITRM930409A1 (it) 1994-12-23
CN1101937C (zh) 2003-02-19
JPH07509571A (ja) 1995-10-19
ES2144524T3 (es) 2000-06-16
CN1538176A (zh) 2004-10-20
ATE189528T1 (de) 2000-02-15
CN1249439C (zh) 2006-04-05
WO1995000852A3 (en) 1995-03-30
DK0656117T3 (da) 2000-07-24
WO1995000852A2 (en) 1995-01-05
CN1112795A (zh) 1995-11-29
JP2643604B2 (ja) 1997-08-20
EP0656117B1 (en) 2000-02-02
DE69422893T2 (de) 2000-08-17
HK1011081A1 (en) 1999-07-02
GR3033111T3 (en) 2000-08-31
AU687416B2 (en) 1998-02-26

Similar Documents

Publication Publication Date Title
PT745094E (pt) Superagonistas e antagonistas da il-6 humana e metodo para a sua seleccao
IT1261787B (it) Metodologia per la selezione di superagonisti, antagonisti e super- antagonisti di ormoni del cui complesso recettoriale fa parte gp 130.
Brakenhoff et al. Structure-function analysis of human IL-6. Epitope mapping of neutralizing monoclonal antibodies with amino-and carboxyl-terminal deletion mutants.
Schroers et al. Dynamics of the gp130 cytokine complex: a model for assembly on the cellular membrane
NO963280L (no) Anvendelse av anti-TNF antistoffer som legemidler i behandling av sykdommer som involverer forhöyede interleukin-6 serumnivåer
NO306678B1 (no) Pyrrolopyrimidiner som CRF-antagonister og farmasöytisk preparat
WO2002012345A3 (en) Soluble zcytor 11 cytokine receptors
DE60328823D1 (de) Hemmung von il-17 produktion
DK1351707T3 (da) Fremgangsmåder til behandling af autoimmunsygdomme hos et individ og in vitro-diagnostiske analyser
DK1353689T3 (da) Immuniseringspræparater og anvendelse deraf
FI960727A0 (fi) Neurokiniiniantagonisteina käyttökelpoiset heterosyklit
DK0840615T3 (da) Kemokin-bindende protein og fremgangsmåder til anvendelse deraf
DK0920509T3 (da) Polypeptider, der er i stand til at danne antigenbindende strukturer med specificitet for Rhesus D-antigener, DNA, der koder herfor, samt fremgangsmåde til fremstilling heraf og anvendelse heraf
PT786002E (pt) Isoforma intracelular do antagonista do receptor da interleuquina-1
WO1994000491A1 (en) INTERLEUKIN-1β DELETION MUTANT
Gallelli et al. Interleukin‐6 receptor superantagonist Sant7 inhibits TGF‐β‐induced proliferation of human lung fibroblasts
JPH03232485A (ja) ハイブリドーマ細胞株の製造方法
WO1995027060A3 (en) Biologically active eph family ligands
CA2218372C (en) Antagonists of human interleukin-6 that are totally incapable of binding gp 130, and their use in the preparation of pharmaceutical compounds
DE69430313D1 (de) Monoklonale antikörper, die flk-2-rezeptoren erkennen, und die isolierung primitiver hämatopoietischer stammzellpopulationen
GB0119015D0 (en) A fusion protein
de Hon et al. Functional distinction of two regions of human interleukin 6 important for signal transduction via gp130
WO2002083847A3 (en) Cdna encoding the human alpha2 delta4 calcium channel subunit
AU7477896A (en) Biologically active eph family ligands
Mirtella et al. Release of Immunoreactive lnterleukin-1-Alpha from Rat Hypothalamic Explants Is Increased by Bacterial Lipopolysaccharide and High KCI Concentrations.

Legal Events

Date Code Title Description
0001 Granted
TA Fee payment date (situation as of event date), data collected since 19931001

Effective date: 19970328